Showing results (491-500 of 626) with videos related to
Sort By:
Pageof 63
Advances in Therapy|August 28, 2025
Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel DiseaseGerd R Burmester, Atul Deodhar, Alan D Irvine, et al.Nature Genetics|June 1, 1997
Mutations in cornea-specific keratin K3 or K12 genes cause Meesmann's corneal dystrophyA D Irvine, L D Corden, O Swensson, et al.JCI Insight|May 8, 2024
Distinct T cell signatures are associated with Staphylococcus aureus skin infection in pediatric atopic dermatitisJulianne Clowry, Daniel J Dempsey, Tracey J Claxton, et al.Proceedings of the National Academy of Sciences of the United States of America|December 28, 2020
Staphylococcus aureus binds to the N-terminal region of corneodesmosin to adhere to the stratum corneum in atopic dermatitisAisling M Towell, Cécile Feuillie, Pauline Vitry, et al.Nature Genetics|June 3, 2000
Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndromeS Chavanas, C Bodemer, A Rochat, et al.Journal of the American Academy of Child and Adolescent Psychiatry|May 10, 2000
Adrenomedullary function during cognitive testing in attention-deficit/hyperactivity disorderG M Anderson, M A Dover, B P Yang, et al.Cancer Research|November 1, 1982
Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasiaT G Pretlow, G B Whitehurst, T P Pretlow, et al.American Journal of Medical Genetics. Part A|January 29, 2011
Identification of a novel C16orf57 mutation in Athabaskan patients with Poikiloderma with NeutropeniaCarol Clericuzio, Karine Harutyunyan, Weidong Jin, et al.The Journal of Investigative Dermatology|July 1, 2006
Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitisAileen Sandilands, Gráinne M O'Regan, Haihui Liao, et al.The New England Journal of Medicine|March 15, 2023
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic DermatitisJonathan I Silverberg, Emma Guttman-Yassky, Diamant Thaçi, et al.Pageof 63